Furthermore, the ability of rTMS to improve the delivery and therapeutic effect of a large biologic, such as the IGF-Trap, without deleterious effects, bodes well for the use of this method to deliver other biologics, such as antibodies, for the treatment of glioma, as well as the management of brain metastases that originated from other primary tumors. The gene discussed is IGF1; the disease is glioma.